TPWA
PTCT icon

Twin Peaks Wealth Advisors’s PTC Therapeutics PTCT Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10
Closed -$681 – 1694
2026
Q1 		$681 Buy
+10
New +$708 ﹤0.01% 1980
2025
Q3 		– Sell
-9
Closed -$407 – 1610
2025
Q2 		$407 Buy
+9
New +$427 ﹤0.01% 1950

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Twin Peaks Wealth Advisors's PTCT Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of PTC Therapeutics (PTCT) in Q2 2026, closing a stake of 10 shares — an estimated $681 sold.

Twin Peaks Wealth Advisors first reported a position in PTCT in Q2 2025 and held it in 2 quarters. The position peaked at $681 in Q1 2026. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining PTC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 10 PTC Therapeutics shares in Q2 2026, an estimated $681.
  • Twin Peaks Wealth Advisors first reported a position in PTC Therapeutics in Q2 2025 and held it in 2 quarters.
  • Twin Peaks Wealth Advisors's PTC Therapeutics position peaked at $681 in Q1 2026.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.